Overview


According to FutureWise analysis the market for Vaccines in 2023 is US$ 50.48 billion, and is expected to reach US$ 111.55 billion by 2031 at a CAGR of 10.40%.

The vaccines market growth can be credited to a rise in the occurrence of infectious diseases, increased financial support from the government for developing vaccines, rising emphasis on immunization, increased research and development activities in enhancing the vaccines. Conversely, the requirement of capital investments for the development of vaccines is huge which shall impede the growth of the market.

The market is fragmented into technology, type, disease indication, route of administration, patient type and region. The technology segment is categorised into inactivated and subunit vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines and recombinant vaccines. The conjugate vaccines held the largest vaccines market share, and this can be primarily credited to a rise in the support of the government, increase in the investments made by key players in developing conjugate vaccines. Based on the route of administration, the market is fragmented into oral administration, intramuscular and subcutaneous administration and other routes of administration. The intramuscular and subcutaneous administration is predicted to proliferate during the forecast period, and this is mainly due to its capability of providing a lower injection site reaction rate and a good immune response.

  • GLAXOSMITHKLINE PLC
  • PFIZER INC.
  • MERCKCo. INC
  • SANOFI PASTEUR SA
  • CSL LIMITED
  • EMERGENT BIOSOLUTIONS
  • JOHNSON & JOHNSON
  • ASTRAZENECA
  • SERUM INSTITUTE OF INDIA PVT. LTD
  • BAVARIAN NORDIC
  • MITSUBISHI TANABE PHARMA CORP.
  • DAIICHI SANKYO CO. LTD.
  • PANACEA BIOTEC LTD.
  • BIOLOGICAL E LTD.
  • BHARAT BIOTECH

(Note: The list of the major players will be updated with the latest market scenario and trends)

Major pharmaceutical companies are creating strategic alliances to develop vaccines for treating COVD-19. For instance, Sanofi and GlaxoSmithKline have partnered to launch a vaccine for novel coronavirus during the second half of 2020. Sanofi will use its S-protein antigen that has produced a protein that genetically matches with the protein present on the surface of the novel coronavirus while GlaxoSmithKline will offer their pandemic adjuvant technology, an immunological agent that is added to a vaccine in order to boost its immune response and produce long-lasting immunity and more antibodies.

Furthermore, Novavax, a biotechnology company based in USA, is planning to partner with Nucleus Network, an Australian company specialized in clinical trials, to initiate the testing of the NVX-CoV2373 vaccine and this will be the first vaccine for COVID-19 to be tested outside the United States. Novavax previously made efforts in developing vaccines for SARS and MERS. This experience shall assist them in developing a vaccine for COVID-19.

By Technology

  • Conjugate Vaccines
  • Inactive and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines

By Type

  • Monovalent Vaccines
  • Multivalent Vaccines

By Disease Indication

  • Pneumococcal Disease
  • DTP
  • Influenza
  • HPV
  • Meningococcal Disease
  • Polio
  • Hepatitis
  • Rotavirus
  • MMR
  • Varicella
  • Herpes Zoster
  • Others

By Route of Administration

  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others

By Patient Type

  • Pediatric Patients
  • Adult Patients
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The North America region is predicted to dominate the global market, and this is mainly due to a high occurrence of infectious disorders and rising investments by private and public organizations for developing vaccines and a strong presence of key market players in the region. The Asia Pacific region is expected to project the highest growth and this mainly due to rise in the disposable income leading to an increased healthcare expenditure, increase in the patient pool and growing initiatives by the government.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
     
  • To provide with an exhaustive analysis on the Vaccines Market By Technology, By Type, By Disease Indication, By Route of Administration, By Patient Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data From Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Global Vaccines Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Pharmaceutical Manufacturers on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Global Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Global Vaccines Market , By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Conjugate Vaccines
        2. Inactive and Subunit Vaccines
        3. Live Attenuated Vaccines
        4. Recombinant Vaccines
        5. Toxoid Vaccines

  • 8.  Global Vaccines Market , By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Monovalent Vaccines
        2. Multivalent Vaccines

  • 9.  Global Vaccines Market , By Disease Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pneumococcal Disease
        2. DTP
        3. Influenza
        4. HPV
        5. Meningococcal Disease
        6. Polio
        7. Hepatitis
        8. Rotavirus
        9. MMR
        10. Varicella
        11. Herpes Zoster
        12. Others

  • 10.  Global Vaccines Market , By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intramuscular and Subcutaneous Administration
        2. Oral Administration
        3. Others

  • 11.  Global Vaccines Market , By Patient Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pediatric Patients
        2. Adult Patients
        3. Others

  • 12.  North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Mexico
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.  Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. GLAXOSMITHKLINE PLC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. PFIZER INC.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. MERCKCo. INC.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. SANOFI PASTEUR SA
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. CSL LIMITED
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. EMERGENT BIOSOLUTIONS
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. JOHNSON & JOHNSON
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. ASTRAZENECA
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. SERUM INSTITUTE OF INDIA PVT. LTD.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. BAVARIAN NORDIC
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. MITSUBISHI TANABE PHARMA CORP.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. DAIICHI SANKYO CO. LTD.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. PANACEA BIOTEC LTD.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. BIOLOGICAL E LTD.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. BHARAT BIOTECH
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME key takeaway points for Client
Partner

Our Clients